News articles about Advaxis (NASDAQ:ADXS) have trended somewhat positive on Sunday, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advaxis earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.1960883122269 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of research analysts recently commented on ADXS shares. BidaskClub upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a report on Wednesday, November 8th. ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $19.00 price target on shares of Advaxis in a research note on Monday, September 25th.

Shares of Advaxis (NASDAQ ADXS) opened at $2.99 on Friday. Advaxis has a 12-month low of $2.71 and a 12-month high of $10.06.

Advaxis (NASDAQ:ADXS) last posted its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.27). The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. equities analysts predict that Advaxis will post -2.21 EPS for the current year.

In other Advaxis news, insider Robert Petit sold 12,625 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total transaction of $40,273.75. Following the transaction, the insider now owns 237,265 shares of the company’s stock, valued at $756,875.35. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the firm’s stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $4.42, for a total value of $5,477,807.66. The disclosure for this sale can be found here. Insiders sold 1,872,291 shares of company stock worth $8,163,810 in the last three months. 7.21% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.